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SUMMARY
Objective: To present the methodology and the results of a field survey to assess the 
chain costs of procedures for treatment of acute myocardial infarction (AMI), carried 
out in 11 Brazilian reference and specialized hospitals. Methods: The cost assessment 
used the cost per procedure and per pathology systems. The procedures associated with 
the treatment of AMI were organized and their logical sequence (protocols) was used to 
create a flowchart. Data collection tools gathered information on prices and quantities 
in 2008 (private, health insurance, SUS, and Brazilian Medical Association – AMB price 
lists), as well as the applicable costs. Results: Overall, the total cost of the procedures 
involving the ‘standard treatment’ of AMI was R$ 12,873.69, if percutaneous coronary 
intervention (PCI) did not involve stent use. If the stent becomes necessary, the cost in-
creases to R$ 23,461.87. Conclusion: Among the results, we emphasize the fact that the 
costs  of the more expensive procedures did not present statistically significant variations 
between hospitals, regardless of their location, predominant clientele or legal nature, and 
the fact that hospitals that treat predominantly users of the Brazilian Unified Health 
System registered the lowest costs, albeit not statistically significant regarding the entire 
chain of procedures associated with the pathology.
Keywords: Hospital costs; costs and cost analysis;  Unified Health System; myocardial in-
farction.
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INTRODUCTION
Since the creation of the Brazilian Unified Health System 
(Sistema Único de Saúde – SUS), much progress has been 
made in terms of decentralization, consensus regarding 
goals between the representatives of the three spheres of 
government, and the introduction of planning mecha-
nisms, among others. However, the services and actions 
of middle and high complexity continue to be paid based 
on volume of service provided, considering values  result-
ing from negotiations between the parties concerned. The 
fact that SUS does not have systems for calculating cost 
contributes to this form of payment.  
Other than that, the specialized literature suggests that 
the characteristics of the health care sector hinder the cal-
culation of their costs. Among these di culties, we high-
light the great irregularity of information between dier-
ent actors and the unpredictability of healthcare need1-3. 
Despite these di culties, this same literature points to at 
least three types of possible costs systems to be applied in 
health: absorption costing,  cost per procedure, and cost 
per pathology (or patient)4. In general, the absorption 
costing system seeks to identify, within each hospital or 
health service, cost centers that represent independent 
production units.
Each cost center can produce intermediate and final 
consumption goods, receiving inputs from external or in-
ternal suppliers. In this sense, one seeks to learn how much 
each cost center absorbs, in terms of value, from other cost 
centers or from external suppliers. Cost centers can be 
classified as direct, indirect, or support cost centers. 
The cost per procedure system is based on thorough 
and necessary analysis for the determination of absorption 
costing. The cost per procedure system is associated with a 
certain medical or surgical intervention and, in general, is 
linked to a cost center. To conduct the survey, the starting 
point is the creation of a classification of procedures and 
knowledge of their inputs and components, as the proce-
dure itself can be considered a product with a certain pro-
duction function. 
A new value is incorporated into this absorption, cre-
ated through the productive eort of the cost center itself. 
The observation of elevated costs for the same procedure 
in a homogeneous set of institutions allows the knowledge 
of both the mean and variance  associated with  this cost, 
and these parameters will be used as reference for the pay-
ment of the service by either the public sector, health in-
surance companies, or by the population. 
The cost per pathology, disease or diagnosis system, in 
theory originates from the cost per procedure system. This 
system is based on the classification of diseases (Interna-
tional Classification of Diseases - ICD), and each disease 
has a set of procedures associated with its treatment. Thus, 
the set of procedures would comprise, in theory, the cost of 
disease or infirmity. However, when the records and infor-
mation are not well developed, one comes to presuppose 
that the patient reacts identically to treatment, resulting, 
in practice, in the application of the cost per procedure. 
This article discusses a field research conducted by the 
“SUS Institutional Development Support Project”, under 
the name “Development and strengthening of the manage-
ment capacity and hospital care within the SUS environ-
ment – survey and development of the cost per procedure 
system in the field of cardiology”. The survey was commis-
sioned by the Brazilian Ministry of Health to be developed 
by Sociedade Hospital Samaritano, under term of adjust-
ment #25000.161051/2008-01, entitled: “Comparative As-
sessment of Cost Models for High Complexity Procedures 
– Excellence Hospitals Standards versus Philanthropic 
Hospitals versus SUS Compensation Lists.” 
In addition to the observed values  and participation of 
dierent categories in the total cost, the methodology used 
for the creation of data collection instruments and the 
analysis methodology are also considered study results. 
Thus, the first part of the article presents the methodology 
adopted for the general assessment of costs of acute myo-
cardial infarction (AMI). The second part, which specifi-
cally addresses AMI, consists of the analysis methodology; 
presentation of “standard treatment” costs; cost analysis of 
other procedure categories, and costs in hospitals that care 
predominantly for the population using SUS. Finally, some 
results are presented and discussed, and some research 
conclusions are presented. This study aims to contribute to 
the construction of a cost system in SUS. 
METHODS
The calculation of the cost of acute myocardial infarc-
tion had, as source of inspiration, the cost per procedure 
system and the cost per pathology system4. For a defini-
tion of procedures associated with this field, we used the 
III Guideline for the Treatment of Acute Myocardial In-
farction of the Brazilian Society of Cardiology, 2004, as 
the source of basic information5. In addition, the follow-
ing protocols were consulted: AMI with ST-segment el-
evation/LBBB new patient care; Albert Einstein Hospital, 
April 2006; I Guideline of Chest Pain in the Emergency 
Room, 2004; the Brazilian Society of Cardiology; and ex-
perts in the field6,7. 
The procedures associated with the treatment of acute 
myocardial infarction were organized according to their 
logical sequence, resulting in a flowchart. Thus, the re-
search instruments were created, which were organized in 
a notebook for collecting data on AMI. We covered fields 
on prices and quantities (private, health insurance, SUS, 
and Brazilian Medical Association – AMB price lists) used 
in 2008, as well as the relevant costs. Prices (as well as SUS 
and AMB values) and amounts surveyed were used as 
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control variables; that is, to assist in the assessment of the 
information regarding the costs. In the case of SUS and 
AMB, the reference values  used were those of the main 
procedure. 
To conduct the survey, information was collected from 
11 excellence and specialized hospitals, which were select-
ed and appointed, by letter, by the Ministry of Health ac-
cording to its own criteria and considered strategic by the 
MH itself. These institutions are located in the states of São 
Paulo (6), Paraná (2), and Rio Grande do Sul (3). 
SUS, through the Ministry of Health, qualified some 
Brazilian hospitals as excellent because they are national 
and international reference in their specialties. Such hos-
pitals have signed terms of adjustment to carry out philan-
thropic projects aimed at improving SUS services. These 
institutions now have a formal link with SUS through the 
development of projects for the assessment and incorpo-
ration of new technologies, training of human resources, 
public interest research, development and management of 
health services. Of the hospitals originally designated by 
the MH, two declined to participate.
The set of procedures associated with the treatment 
of AMI has been classified into five categories: standard; 
alternative; due to special procedures; procedures not es-
sential for the diagnosis of AMI, which may or may not be 
performed as a complementary procedure; and outdated 
procedure, which can be seen in Figure 1. In addition, pro-
cedures were grouped into preoperative (1 and 2), surgical 
(3 and 4), and postoperative (5), or diagnosis, interven-
tion, and follow-up. When the control procedures were 
performed several times, depending on the duration of 
hospital stay, only one event was recorded regarding the 
pre- and post-operative values  . 
Data collected refer to the procedures performed dur-
ing 2008 by the participating hospitals. Costs are shown 
in currency values, and no monetary value update was 
carried out . Comparison of results between groups 
was submitted to mean comparison test by both the “t” 
test (parametric) and the c2 test (nonparametric), whenev-
er possible, because the sample sizes varied widely among 
the analyzed procedures. 
The calculated mean exchange rate for the year 2008 
was R$ 1.8346 per US$ 1, which is used to convert the 
mean values for the year 2008 obtained in this study for 
purposes of international comparisons. 
RESULTS
THE COST OF THE STANDARD TREATMENT OF AMI
The total cost of the procedures involving the standard 
treatment of AMI in 2008 was R$ 12,873.69 if the per-
cutaneous coronary intervention (PCI) did not involve 
stent use. If the stent becomes necessary, the cost rises to 
R$ 23,461.87.
PER PROCEDURE
Within the standard treatment, the higher cost proce-
dures are cardiac catheterization with coronary angiogra-
phy and PCI. If one considers the primary or rescue PCI 
(i.e., without stent use), these two procedures represent, 
respectively, 28.6% and 67.7% of the total cost. When 
stent implantation is considered, these percentages change 
to 15.7% and 82.2%, respectively. The costs of these two 
procedures do not show significant variations among the 
hospitals surveyed, regardless of whether they treat only 
the SUS population, have “double doors” or if they treat 
only private or health insurance patients, or even patients 
from its geographic location, although the costs of those 
that treat predominantly SUS patients are generally lower. 
Similarly, no significant dierence was identified between 
the private, public, and philanthropic hospitals. For these 
two procedures, the coe cients of variation were 12.9% 
and 5.6%, significant at 5% and 1%, respectively. The vari-
ances observed are high for the pre-or post-operative pro-
cedures and of lower individual value, such as ECG, CK-
MB and serum troponin levels, chest X-ray and creatinine, 
urea, sodium, potassium and blood count tests, all with a 
coe cient of variation > 40% (not significant at 5%).  
PER CATEGORY
Within the survey, the cost analysis by category was re-
stricted to only the two main procedures in the standard 
treatment of AMI: cardiac catheterization with coronary 
angiography and PCI. 
a) Cardiac catheterization with coronary angiogra-
phy: The distribution of cost for cardiac catheterization 
with coronary angiography shows that costs of sta (doc-
tors, anesthesiologists, nurses, technicians, and support 
and diagnosis sta ) correspond to 44.0%; facilities (inten-
sive care unit, nursing or hospital fees, the use of operating 
room and the facilities themselves) correspond to 40.1%; 
equipment 10.3%; and medications 5.6%. 
b) Primary or rescue percutaneous coronary inter-
vention: Four scenarios were considered. 
1) Standard: Regarding the normal cost of an inter-
vention during which there are no complications, the 
elements of highest weight in the total cost are material, 
including balloon catheter for percutaneous translumi-
nal angioplasty, guide catheter for percutaneous trans- 
luminal angioplasty, guide wire for angioplasty and valve 
introducer (37.4%); sta, including physician, anesthesiol-
ogist, and physical therapist (29.7%); ICU daily fees; nurs-
ing and hospital fees (16.4%); use of the operating room 
(10.1%); and other components, such as laboratory tests, 
medications, and imaging tests (6.5%).
COSTS OF THE CHAIN OF TREATMENT PROCEDURES IN ACUTE MYOCARDIAL INFARCTION IN BRAZILIAN REFERENCE AND SPECIALIZED HOSPITALS
107Rev Assoc Med Bras 2012; 58(1):104-111
Surg/MV
Surg/Rupt
Surg/Aneu
or
or
or
Very rare
from shock
Basic chain of procedures in the treatment of AMI
ĂƵƐĞĚďǇĐŽŵƉůŝĐĂƟŽŶ
ůƚĞƌŶĂƟǀĞƉƌŽĐĞĚƵƌĞƐ
Possible, but not mandatory procedures
Technically outdated procedures
Congenital problems
or
;ϮͿŝůĂƚĞƌĂůǀĞŶŽƵƐĂĐĐĞƐƐ
Oxygen (for 6 hours)
(2) Pulse oximetry 
(2) Serum troponin assessment Fibrinolysis
(4) Primary PCI
(4) PCI with stent
(4) Rescue PCI
CGREVASC
(5) MON/SST
(5) ARR/COM
(5) UREA
(5) CREAT
(5) SODIUM
(5) POTASSIUM
(5) CBC
ECV
VF
ETI
;ϭͿŵĞƌŐĞŶĐǇĐŽŶƐƵůƚĂƟŽŶΎ
(2) CK-MB assessment
GOP
GPT
DLH
Surg/Peric
Peri/Drain
Pericardiocentesis
Bpump
ERep
TVPM
TCPM
;ϯͿĂƚŚĞƚĞƌŝǌĂƟŽŶн
(2) Chest X-ray
Per Cann
(2) Gaso
UV
ECHO
(2) ECG
Echo, echocardiogram; ECG, electrocardiogram; Emerg Surg, emergency surgical procedure; Bpump, balloon pump; ERep, early reperfusion; 
^ƵƌŐͬWĞƌŝĐ͕ ƐƵƌŐŝĐĂů ŝŶƚĞƌǀĞŶƟŽŶͬƉĞƌŝĐĂƌĚŝƟƐ͖ WĞƌŝͬƌĂŝŶ͕ ƉĞƌŝĐĂƌĚŝĂů ĚƌĂŝŶĂŐĞ͖ DKEͬ^^d͕  ŵŽŶŝƚŽƌŝŶŐ ŽĨ ^^d ƐĞŐŵĞŶƚ͖ ZZͬKD͕ ĂƌƌŚǇƚŚŵŝĂ
ĐŽŶƚƌŽů͖hZ͕ƵƌĞĂůĞǀĞůƐ͖Zd͕ ĐƌĞĂƟŶŝŶĞůĞǀĞůƐ͖^K/hD͕ƐŽĚŝƵŵůĞǀĞůƐ͖WKd^^/hD͕ƉŽƚĂƐƐŝƵŵůĞǀĞůƐ͖͕ĐŽŵƉůĞƚĞďůŽŽĚĐŽƵŶƚ͖^ƵƌŐͬ
ŶĞƵ͕ ƐƵƌŐŝĐĂů ŝŶƚĞƌǀĞŶƟŽŶ͕ ĂŶĞƵƌǇƐŵ͖ ^ƵƌŐͬZƵƉƚ͖ ƐƵƌŐŝĐĂů ŝŶƚĞƌǀĞŶƟŽŶ͕ ƌƵƉƚƵƌĞ͖ ^ƵƌŐͬDs͕ ƐƵƌŐŝĐĂů ŝŶƚĞƌǀĞŶƟŽŶͬŵŝƚƌĂů sĂůǀĞ͖ s͕ ĞůĞĐƚƌŝĐĂů
ĐĂƌĚŝŽǀĞƌƐŝŽŶ͖dWD͕ƚƌĂŶƐĐƵƚĂŶĞŽƵƐƉĂĐĞŵĂŬĞƌŝŵƉůĂŶƚ͖dsWD͕ƚƌĂŶƐǀĞŶŽƵƐƉĂĐĞŵĂŬĞƌŝŵƉůĂŶƚ͖͕ĐŽƌŽŶĂƌǇĂŶŐŝŽŐƌĂƉŚǇ͖d/͕ĞŶĚŽƚƌĂĐŚĞĂů
ŝŶƚƵďĂƟŽŶ͖'ĂƐŽ͕ŐĂƐŽŵĞƚƌǇ͖WĞƌĂŶŶ͕ƉĞƌŝƉŚĞƌĂůĐĂŶŶƵůĂƟŽŶ͖hs͕ƵƌŝŶĂƌǇǀŽůƵŵĞ͖s&͕ ǀĞŶƚƌŝĐƵůĂƌĮďƌŝůůĂƟŽŶ͖D/͕ĂĐƵƚĞŵǇŽĐĂƌĚŝĂůŝŶĨĂƌĐƟŽŶ͖
*the numbers follow the order of procedures.
Figure 1 –  Flowchart of standard treatment procedures in acute myocardial infarction.
Hemodynamic 
analysis
2) Additional cardiac catheterization (ACC): When 
there is a need for ACC, the distribution of cost  accounts 
for material (25.9%); daily fees (22.5%); sta (21.5%); ad-
ditional catheterization (13.6%); operating room (5.6%); 
and other components (10.9%). This new cost distribution 
is due to the new intervention and the increase in hospital 
stay, which implies greater need for medications.
3) Special medication: When it involves the use of drugs 
(abciximab was the only one reported by hospitals), the 
relative weight of the main components that comprise 
the cost changes to medication (49.8%); daily fees (21.0%); 
material (12.0%); sta (9.6%); and use of the operating 
room (2.7%). This new distribution is fully dependent on 
the significant value of the special medication.
4) Longer stay in hospital: If the patient’s condition re-
quires a longer hospital stay, the cost distribution is based 
on material (32.0%); daily fees (27.2%); sta (21.3%); op-
erating room (6.9%); and others (12.6%). The increase in 
costs of laboratory tests is due to the repetition of the same 
tests during the hospitalization period.
c)  Coronary angioplasty with stent implantation – 
PCI with stent: Five situations were considered.
1) Standard: Cost distribution is based on material, in-
cluding stent (63.3%); sta (17.3%); daily fees (10.3%); use 
of operating room (5.6%), and others (3.5%).
2) Additional catheterization: The cost distribution 
changes as the additional catheterization results in longer 
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hospital stay, increasing the participation of hospital dai-
ly fees to 20.0%. The other cost items include material 
(49.6%); sta (13.4%); additional catheterization (8.2%); 
use of operating room (4.0%); and  others (4.8 %).
3) Special medication (abciximab): The cost distribu-
tion comprises medications (49.3%); material (31.9%); 
sta (8.8%); daily fees (6.3%); use of operating room 
(2.4%); and others (1.3%). 
4) Longer stay in hospital:Requiring more than two 
days at the ICU, emergency room, and infirmary, the daily 
fees become relevant in the cost distribution (22.1%), al-
though the costs with material remain the highest (53.3%). 
The other cost items include sta (14.8%); use of operating 
room (4.2%); and others (5.6%).
5)Special medications and additional catheterization: 
If the patient requires special medications and an addition-
al catheterization, the cost distribution comprises medi-
cation (43.6%); material (30.2%); daily fees (9.1%); sta  
(8 1%); additional catheterization (5.0%); use of operating 
room (2.2%); and others (1.8%). 
THE COST OF AMI TREATMENT WITH ADDITIONAL AND SPECIAL 
PROCEDURES
COMPLEMENTARY PROCEDURES
If non-essential procedures are performed – here called 
complementary, such as urine volume control, GOT and 
GPT tests, and echocardiogram (intraoperative or not), 
the cost may increase by R$ 252.40 or R$ 866.99, respec-
tively. Note that, for these procedures, the relationship 
between  mean and standard deviation is significant (i.e., 
greater than 32%). When the procedure does not incur 
high cost (compared to the other), the variation in the 
value reported by hospitals is high.
The appropriation of these costs to the treatment of 
AMI can increase the cost by 2% when the use of Doppler 
echocardiography precedes the primary or rescue PCI. If 
Doppler ultrasound is performed intraoperatively, the cost 
increases by 6.7%. In the case of PCI with stent, the costs 
rise by 1.1% for the first and 3.7% for the second. 
None of the hospitals reported values  for fibrinolysis 
and peripheral venous cannulation procedures, consid-
ered as alternatives.
SPECIAL PROCEDURES
In the event of coronary artery bypass, transcutaneous 
pacemaker implantation, transvenous pacemaker implan-
tation, pericarditis surgery, pericardiocentesis, pericar-
dial drainage, endotracheal intubation or cardioversion 
(ventricular fibrillation), the cost rises significantly. These 
special procedures may increase the cost of standard treat-
ment by up to fieen times if such treatment includes the 
primary or rescue PCI or up to nine times when treat-
ment includes stenting. Information regarding special 
procedures, obtained from the hospitals, reported extreme 
variation, except for pericardiocentesis. 
Among the special procedures reported in the survey, 
we stress the coronary artery bypass gra surgery, popu-
larly known as “CABG”, due to its high frequency. 
a)Myocardial revascularization: At the cost analysis, 
nine cases depending on the patient’s history and response 
to surgery were seen: the standard case (with no special 
procedures) at a cost of R$ 8,674.86; long hospital stay 
(R$ 10,481.53); additional catheterization (R$ 9,452.53); 
disposable intraortic balloon implantation (R$ 11,588.72); 
additional catheterization and disposable intraortic bal-
loon implantation (R$ 13,987.87); use of special medi-
cations (R$ 14,091.04); use of special medications and 
additional catheterization (R$ 14,128.02); use of special 
medication and disposable intraortic balloon implantation 
(R$ 15,906.12); and use of special medication, disposable 
intraortic balloon implantation, and additional catheter-
ization (R$ 17,535.99).  
When comparing these dierent situations with those 
without any additional procedures, called here the stan-
dard CABG surgery, the cost is greatly increased by the 
procedure direct cost. For instance, when the disposable 
intraortic balloon implantation is necessary, material par-
ticipation in total cost increases from 41.7% (standard 
case) to 50.2%, whereas the use of special medication 
increases the participation of drugs from 3.7% (standard 
case) to 35.2%. The cost and its distribution by component 
in all nine situations can be seen in Table 1.
DISCUSSION
Broadly speaking, the total cost of AMI standard treat-
ment in 2008 was R$ 12,873.69, equivalent to US$ 7,017 
(1 U.S. dollar in 2008 = R$ 1.8346). It was also veri-
fied that, if necessary, the PCI with the use of stent costs 
R$ 23,461.87, equal to US$ 12,789. In this perspective, it 
may be mentioned that the cost obtained by the research, 
when compared to international studies, is quite similar. Ac-
cording to Kauf et al.8 in a comparative study of nine coun-
tries including the United States, when characterizing the 
cost of initial hospitalization for AMI, it indicated a total of 
US$ 9,993. To get an idea on  cost information in other coun-
tries, Busse et al. 9 show, in a comparative study in the Euro-
pean Union, that there is a wide variety of results between 
countries. In the Netherlands, the cost of AMI treatment 
was 8,722 euros, which corresponds to R$ 28,243 (2008 
data), while in neighboring Germany it was only 3,114 euros 
(US$ 10,083). 
Noteworthy, Busse et al.8 emphasize that the cost dif-
ferences are due to the dierent characteristics of exist-
ing treatments in dierent countries. Among them, the 
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Situation Daily fee Material  staff Medication 
Operating 
room
Others* Mean value
Increase 
%**
Standard 13.0% 41.7% 28.2% 3.7% 6.4% 7.0% R$ 8,674.86 –
Additional catheterization 15.7% 37.7% 25.7% 3.3% 5.2% 12.4% R$ 9,452.53 9.0%
Long hospital stay 27.5% 35.0% 23.5% 3.6% 4.6% 5.8% R$10,481.53 20.8%
Intra-aortic balloon 16.2% 50.2% 21.2% 2.9% 3.9% 5.6% R$11,588.72 33.6%
Catheterization + intra-aortic balloon 21.6% 43.1% 19.3% 2.4% 4.0% 9.6% R$13,987.87 61.2%
Special medication 15.3% 26.1% 17.3% 35.2% 3.0% 3.1% R$14,091.04 62.4%
Special medication + catheterization 11.0% 26.2% 17.1% 35.4% 2.8% 7.5% R$14,128.02 62.9%
Special medication + intra-aortic 
balloon
13.4% 34.7% 15.3% 31.2% 2.4% 3.0% R$15,906.12 83.4%
Special medication + catheterization  
+ intra-aortic balloon
17.5% 32.6% 13.8% 28.2% 2.3% 5.6% R$17,535.99 102.1%
Source: Information supplied by the participant hospitals; * includes imaging tests, laboratory tests, transfusion, and additional catheterization; ** increase in total cost related to 
standard treatment.
Table 1 – Cost distribution of on-pump myocardial revascularization (with two or more grafts) according to situations caused 
by complications, per component cost in 2008
authors point out: a) dierences in the type of care pro-
vided, including the chosen technologies and the several 
human resources skills employed; b) the intensity at which 
the technology or sta are used in each treatment; c) dif-
ferences in the costs of implemented procedures; d) deter-
mining the extent of the type of hospital service employed; 
e) the accounting treatment of the related services, such as 
whether anesthesia is included in the surgical procedure or 
appropriate, and charged separately.  
Certainly, these cost dierences in AMI treatment can 
also be applied to the case of Brazil. Thus, it is possible to 
agree with Busse et al.8 when they say that the cost com-
parison  between countries must always take into account 
the dierent features in existing treatments. This finding 
may be verified in the survey carried out in Brazilian hos-
pitals of excellence.
Furthermore, the data analyzed in this study allow us 
to identify that any complications substantially alter the 
costs of treatment of AMI.
If the primary or rescue PCI (coronary angioplasty) 
require an additional catheterization, the cost rises 40.7% 
(R$18,113.28); if it required a long hospital stay, the cost is 
50.3% higher than the standard treatment (R$19,349.16); 
and if it involves the need to use special medication (ab-
ciximab), the cost is 211.3% (R$40,075.80) higher than the 
standard treatment. 
For PCI involving stenting (coronary angioplasty with 
stent implant), the need for catheterization involves ad-
ditional 27.7% increase in the cost of treatment, totaling 
R$29,960.81; a long hospital stay increases the cost by 
20.7% (R$28,318.48); the use of special medication in-
creases the cost by 99.1% (R$46,712.58); and if treatment 
requires special medication and an additional catheteriza-
tion, the total cost is R$49,199.54 (109.7% above the stan-
dard treatment with stent).
The research pointed out that the need to use special 
procedures, such as coronary artery bypass; transcutane-
ous pacemaker implantation; transvenous pacemaker im-
plantation; pericarditis surgery; pericardiocentesis; peri-
cardial drainage; endotracheal intubation or cardioversion 
(ventricular fibrillation), greatly increases the cost of treat-
ment of AMI, which can be 15 times higher than the cost 
of standard treatment. However, the cost of the special 
procedures provided by the analyzed hospitals varied sub-
stantially, not allowing us to obtain a representative mean. 
The total cost of the chain of AMI treatment proce-
dures in hospitals that treat predominantly SUS patients 
is 21.6% lower than the cost of the set of procedures in 
all hospitals analyzed. However, this result is within a sta-
tistically acceptable range of variation; i.e., values  are not 
significantly dierent at 5% significance level. For some 
procedures the mean cost of hospitals that treat predomi-
nantly SUS patients was not compared with the mean cost 
of other hospitals due to insu cient data.
The procedures that showed more significant dier-
ences compared to the mean observed for all hospitals 
in the study were exactly those of lower cost, with the ex-
ception of CBC and follow-up. As for the more expensive 
procedures, such as catheterization and PCI, the dierence 
was small (Table 2).
CONCLUSION
Our research has indicated that it is appropriate to use 
chains of procedure associated with pathology for cost 
analysis.
For AMI, this method allowed us to define a standard 
treatment, especially considering the alternative proce-
dures and those resulting from special procedures, as well 
as nonessential and outdated ones. Also in relation to AMI, 
it was possible to group the preoperative, intraoperative, 
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Table 2 – Comparison of mean costs among all hospitals and those treating predominantly SUS patients 
Components All hospitals R$ SUS hospitals R$ Difference
Consultation 48.71 10.50 -78.4%
ECG 59.94 13.17 -78.0%
Bilateral venous access 50.00 –
CK-MB assessment creatine phosphokinase fraction 35.98 3.32 -90.8%
Gasometry 23.64 5.17 -78.1%
Serum troponin 43.04 3.32 -92.3%
Oximetry 11.54 1.53 -86.7%
Chest X-ray 57.58 22.97 -60.1%
Cardiac catheterization with coronary angiography 3,681.14 2,517.58 -31.6%
Primary or rescue PCI 8,709.84 7,407.30 -15.0%
Monitoring 114.15 76.68 -32.8%
Creatinine 5.90 3.53 -40.2%
Urea 7.20 4.83 -32.9%
Sodium 6.44 3.53 -45.2%
Potassium 6.39 3.53 -44.8%
Complete blood count 12.20 12.87 5.5%
Total primary or rescue PCI 12,873.69 10,089.82 -21.6%
Source: Information supplied by participating hospitals; PCI, percutaneous coronary intervention.
and post-operative procedures, or as procedures related to 
diagnosis, intervention, and follow-up/control.
In the standard treatment of AMI, procedures that 
involve greater cost are cardiac catheterization with cor-
onary angiography and PCI, which together represent 
96.2% of the total cost of primary or rescue PCI and 97.9% 
of PCI with stent implantation. Statically speaking, the 
costs of these procedures did not show significant dier-
ences (5% significance level) between hospitals; therefore, 
the geographical location, clientele, and nature of hospitals 
(public, private, philanthropic) are not relevant. 
The cost of cardiac catheterization with coronary angi-
ography is strongly associated with sta (44.0%) and facili-
ties (40.1%) costs.
The cost of PCI varies substantially when there are 
complications and may be 211.3% higher than the cost 
of standard treatment with primary or rescue PCI (e.g., 
if a long hospital stay is necessary, or in case of addition-
al catheterization or use of special medication) or up to 
109.7% higher than the standard treatment with PCI and 
stent implantation. Regarding cost composition for AMI 
treatment in which special procedures will not be neces-
sary, we highlight material, sta, daily fees, and special 
medication (abciximab) costs. 
The costs associated with additional procedures to con-
trol urine volume, GOT and GPT tests, and echocardio-
gram (intraoperative or not) showed significant variation 
among the hospitals analyzed. These procedures, however, 
carry little weight in the total cost of AMI treatment. 
The existence of special procedures, such as coro-
nary artery bypass, transcutaneous pacemaker im-
plantation, transvenous pacemaker implantation, 
surgical procedure due to pericarditis, pericardiocen-
tesis, pericardial drainage, endotracheal intubation 
or cardioversion (ventricular fibrillation) significant-
ly increases the cost of AMI treatment (up to fieen 
times) if such treatment encompasses the primary 
or rescue PCI, and up to nine times, when the treat-
ment involves the implantation of stent, although 
the values  vary widely among the hospitals analyzed. 
In the specific case of myocardial revascularization, the 
cost ranges from R$8,674.86 to R$17,535.99 if the pa-
tient requires long hospital stay, an additional catheter, 
intra-aortic balloon implantation, or special medication.
The total cost of the chain of AMI treatment proce-
dures in hospitals that treat predominantly SUS patients, 
although 21.6% lower than the cost of the group of all 
hospitals analyzed, is not significantly shown by the latter. 
The procedures that have more significant dierences re-
garding the mean observed for all the hospitals are exactly 
those of lower cost, with very little dierence to the pro-
cedures of greater monetary value, such as catheterization 
and PCI.
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